key: cord-0746257-hc40gvqk
authors: Obermann, Mark; Krasniqi, Maliqe; Ewers, Nadja; Fayad, Jaber; Haeberle, Uta
title: Bell’s palsy following COVID-19 vaccination with high CSF antibody response
date: 2021-07-29
journal: Neurol Sci
DOI: 10.1007/s10072-021-05496-5
sha: 4be42c70e7ba4aea4b06f7c42a08c620bec39dee
doc_id: 746257
cord_uid: hc40gvqk

nan

A 21-year-old nurse working in a retirement home developed right facial palsy 2 days after receiving her first dose of SARS-CoV-2 mRNA vaccine Comirnaty (BNT162b2, BioNTech/Pfizer). She reported that she experienced a slight tingling sensation the day after vaccination and woke up the second day after vaccination with facial muscle paralysis (Fig. 1) . There was minimal muscle tenderness at injection site but no other side effects. She presented to our emergency unit 10 days after symptom onset. Magnetic resonance imaging (MRI) of her head showed no intracranial lesion, or other pathology. Cerebrospinal fluid (CRF) analysis was unremarkable with 2 cells/µl, normal protein (0.41 g/l), lactate, and glucose. Herpes simplex type 1 (HSV), varicella-zoster-virus (VZV), measles virus, and Borrelia antibodies were negative. Motor-evoked potentials (MEP) to the musculus nasalis showed normal latency and amplitude on the left side from cortical, temporal stimulation over the petrous bone, as well as stimulation over the stylomastoid foramen, while the right side did not elicit any potential (Fig. 2) . SARS-CoV-2 antibodies against the S1-protein were detectable in blood and CSF using the commercially available Anti-SARS-CoV-2-ELISA (Euroimmun) demonstrating a good immune response to the first vaccination (SARS-CoV-2-IgA: 4.5 ratio, neg: < 0.8, pos: > 1.0; SARS-CoV-2-IgG: 5.4 ratio, neg: < 0.8, pos: ≥ 1.0, SARS-CoV-2-IgG quant. > 288.0 BAU/ml (BAU = binding antibody units)). SARS-CoV-2-IgG AI (antibody index) serum was 64.3 RU/ml (RU = relative units of quantification), CSF was 19.8 RU/ml, and SARS-CoV-2-IgG AI was 86. Total IgG serum was 927 mg/dl; total IgG CSF was 33 mg/l. The coronavirus SARS-CoV-2-RNA test was negative to exclude acute infection (Roche Elecsys Anti-SARS-CoV-2 negative: 0.07 COI (cutoff index), neg: < 1.0, pos: ≥ 1.0).

The patient was treated with oral prednisolone 100 mg per day over 5 days, was shown face muscle training, and received eye protecting ointment and an overnight eye patch. She was discharged 3 days after admission and reported that she tolerated treatment well and started to regain lid closure without substantial improvement of her lower facial muscles.

This would be the eleventh confirmed case in Germany since the start of the surveillance program accompanying the vaccination efforts (27.12.2020-31.01.2021) out of 2,432,766 people that were vaccinated (2.2 per 100,000 persons) [3] . Even though the causal relationship between vaccination and onset of Bell's palsy remains uncertain, the temporal relationship of clinical symptoms and vaccination is much more plausible than what was reported from the clinical trials. In two reported cases, the onset of symptoms was only hours from vaccination, so that an effect from vaccination seems rather unlikely. In other cases, it remains uncertain whether the facial nerve was genuinely affected [1] [2] [3] .

We tried to clearly demonstrate the affection of the facial nerve using motor-evoked potentials and also demonstrated the successful vaccination by quantification of antibodies against the spike protein (S1). The high antibody index (AI) comparing serum and CSF might even be interpreted as a potentially overwhelming vaccine response, or more than usual penetration in the central nervous system, so that the facial nerve could get affected. Would a high AI be a risk factor to develop Bell's palsy after vaccination and should it lead to early diagnosis and swift treatment in order to prevent long-term damage to the facial nerve?

Bell's palsy is usually a benign condition with high spontaneous recovery rates of 71%. Sequelae were generally slight in 12% of patients, mild in 13%, and severe only in 4% [4] .

The estimated incidence rate of Bell's palsy in the general population ranges from 15 to 30 cases per 100,000 person-years. Since the 40,000 vaccine arm participants were followed for a median of 2 months, the combined safety population receiving vaccine across the two trials represents roughly 6700 person-years of observation time for an expected incidence of Bell's palsy of one to two cases, in line with the single observed case in the combined placebo arms. Therefore, the observed incidence of Bell's palsy in the vaccine arms is between 3.5 and 7 times higher than would be expected in the general population [5, 6] .

A recent study form northern Italy demonstrated a higher incidence of Bell's palsy in patients suffering from COVID-19 than would be expected from data of the previous year in that same region, so that an immunologic mechanism might be associated with the infection as well as with the vaccination [7] . This hypothesis is emphasized by the fact that other viral vaccines, e.g., hepatitis B recombinant vaccine or influenza vaccine, were also suspected to lead to transient facial nerve paralysis [8, 9] . Mimicry of host molecules or bystander activation of dormant autoreactive T cells was discussed as possible pathophysiological mechanism [10] . The vaccine might also induce innate immune activation and production of interferon proteins leading to facial nerve palsy [11] . More research is needed to unravel the potential pathophysiological mechanisms or to assure an incidental coexistence of vaccination and Bell's palsy, respectively.

The causal relationship between vaccination and the development of Bell's palsy remains uncertain. The temporal relationship to the vaccination should encourage health care professionals to be vigilant toward people developing Bell's palsy after SARS-CoV-2 vaccination with mRNA vaccine. Diagnosis and treatment should be swift and decisive.

Author contribution MO and UH wrote the first draft of the manuscript, MK and JF diagnosed and treated the patient, and NE did the blood and CSF analysis. All authors read and approved the final manuscript.

Data availability Not applicable.

Ethical approval Ethics approval was waived.

Consent for publication Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review.

The authors declare no competing interests.

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Practical management of Bell's palsy. Otolaryngol-Head

Practice parameter: steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

Bell's palsy: a prospective study

Facial palsy during the COVID-19 pandemic

Transient facial nerve paralysis (Bell's palsy) following administration of hepatitis B recombinant vaccine: a case report

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

Do vaccines have a role as a cause of autoimmune neurological syndromes? Front Public Health

Bell's palsy and SARS-CoV-2 vaccines